MindWalk Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 46% year-over-year with gross margin expanding to 59%, while net loss narrowed by more than half. First recurring SaaS revenue was booked, and strategic divestitures strengthened the balance sheet. Market focus is shifting to proprietary data and context, validating the platform's unique position.
-
Revenue grew 52% YoY in Q3 2026, driven by U.S. expansion and the first recurring LensAI contract. Pipeline programs advanced, cash position remains strong, and asset-level financing is in progress.
-
Second quarter saw 54% revenue growth and a 94% increase in gross profit, driven by scalable AI-enabled programs and the divestiture of non-core assets. A strong cash position and new asset portfolio structure support continued investment and protect shareholders from dilution.
-
Record Q1 revenue and margin expansion were achieved, with improved operating results and a strengthened balance sheet following the Netherlands divestiture. The rebranding to MindWalk Inc. and focus on AI-driven platforms position the company for scalable growth and new partnerships.
Fiscal Year 2025
-
Record Q4 revenue and margin expansion driven by BioStrand's triple-digit growth and operational efficiency. Major partnerships, AI platform advances, and a strong cash position set the stage for continued growth, with divestiture and rebranding to sharpen focus.
-
Secured a transformative $8–$10 million partnership, achieved 131.8% BioStrand revenue growth, and raised $8.8 million in equity, while maintaining a 97% gross margin in AI. Ongoing EU divestiture and cost-saving AI collaborations are expected to further enhance profitability.
-
Q2 FY2025 revenue was flat year-over-year but up 16% sequentially, with BioStrand achieving record revenue and high gross margins. Strategic moves include relocating HQ to Austin, divesting European wet labs, and focusing on AI-driven platforms for higher growth and profitability.
-
Q1 FY2025 revenue reached CAD 5.3 million, with strong growth at two sites and robust demand for AI-driven antibody discovery. Net loss widened due to increased R&D, but a strong pipeline and strategic licensing position the company for future growth.
Fiscal Year 2024
-
Achieved record revenue for the fifth consecutive quarter, with fiscal 2024 revenue up 19% year-over-year and significant progress in AI-driven drug discovery. Gross margin declined due to expansion, but cash burn was sharply reduced, and the company expects continued above-market growth in fiscal 2025.